ABVC enters global licensing deal for Vitargus; potential total fees of $33.5M plus royalties up to $60M

ABVC BIOPHARMA, INC.

20-year exclusive global license with ForSeeCon Eye Corp for ophthalmology pipeline including Vitargus.
ABVC and co-development partner BioFirst each to receive $30M upfront (cash or 5M shares of FEYE at $6/share) within 30 days.
Additional $3.5M cash milestone per party after next fundraise; 5% royalty on net sales capped at $60M per entity.
Vitargus valued at $187M by third-party valuer; ABVC retains R&D role for ophthalmic products.
License covers clinical trial, registration, manufacturing, supply, and distribution rights.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.